Stock events for Design Therapeutics, Inc. (DSGN)
Design Therapeutics' stock price has increased significantly due to positive analyst actions and clinical trial updates. Key events include analyst upgrades and price target increases from RBC Capital Markets, Leerink Partners, Oppenheimer, and Craig-Hallum. A clinical hold on a U.S. IND application for DT-216P2 in June 2025 was offset by an ongoing trial in Australia and projected data from the RESTORE-FA Phase 1/2 trial.
Demand Seasonality affecting Design Therapeutics, Inc.’s stock price
As a clinical-stage biopharmaceutical company, Design Therapeutics currently generates no revenue from commercial product sales. Therefore, traditional demand seasonality is not applicable at its current stage of development.
Overview of Design Therapeutics, Inc.’s business
Design Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious degenerative genetic disorders, specifically GeneTAC molecules. The company's major programs include treatments for Friedreich ataxia, Fuchs Endothelial Corneal Dystrophy, Huntington's Disease, and Myotonic Dystrophy Type-1.
DSGN’s Geographic footprint
Design Therapeutics is headquartered in Carlsbad, California, and primarily conducts its research, development, and commercialization efforts in the United States. Clinical trials are also ongoing in other regions, including Australia.
DSGN Corporate Image Assessment
Design Therapeutics has maintained a positive brand reputation, particularly within the analyst community, with a consensus rating of "Moderate Buy". Analyst upgrades and increased price targets reflect confidence in the company's pipeline. The clinical hold on DT-216P2 was mitigated by the ongoing trial in Australia and anticipated data readout. The appointment of Justin Gover to the Board of Directors signals a focus on commercialization.
Ownership
Design Therapeutics has significant institutional ownership, with 210 institutional owners holding 60.83% of the company's shares. Insiders hold 23.50%, and retail/public investors hold 15.67%. Major institutional owners include SR One Capital Management, LP, Logos Global Management LP, and Point72 Asset Management, L.P.. Simeon George is a major individual holder among insiders.
Ask Our Expert AI Analyst
Price Chart
$10.34
